Corrections

In the meta-analysis of β-blockers for the treatment of hypertension by Nadia Khan and Finlay McAlister,¹ there were typographic errors in the numbers reported on the right-hand side of Figs. 2A and 2B. None of the typographic errors were incorporated in the analyses, and thus there was no effect on the findings or interpretation of the findings. The corrections are summarized here.

Fig. 2A: For the Medical Research Council trial, the denominator for “other drug” should read 4297 (instead of 8654). The overall denominator was 14 708 for the β-blocker group and 14 638 for the “other drug” group.

Fig. 2B: The overall denominator was 42 598 for the β-blocker group and 44 582 for the “other drug” group. The p value for heterogeneity should be 0.08, not 0.8. The pooled summary estimate was 1.07 (95% CI 1.00–1.14).